Overview
Neutralizes extracellular myostatin and activins, preventing them from signaling through ActRIIB on muscle cells.
Proposed mechanism
ACVR2B-Fc is a decoy receptor that binds myostatin and activins with high affinity, preventing them from activating the native ActRIIB receptor.
What the evidence supports
Evidence rests primarily on self-reported experience. Controlled studies are lacking.
Graded Anecdotal
Case reports, clinician notes, and user-reported outcomes. Recorded for completeness and labelled plainly so it is never mistaken for data.
Key citations
Representative primary sources, including results that did not favour the compound.
- [1]
ACE-031 clinical trial
· DOI:10.1016/j.nmd.2011.06.1023 · 2011
- [2]
Myostatin inhibition therapies
· DOI:10.1172/JCI37552 · 2008
- [3]
ACE-031 clinical trial (2011)
· · 0
- [4]
Myostatin inhibition therapies (2008)
· · 0
Citation records in this build are illustrative placeholders for the design.
Reference information for research purposes. Not medical advice, and not a recommendation to use any compound. Many entries describe substances that are not approved for human use.